Current status and future perspectives for yttrium-90 (90Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma

被引：0

作者：

C Gisselbrecht

W Bethge

R F Duarte

A M Gianni

B Glass

C Haioun

G Martinelli

A Nagler

R Pettengell

A Sureda

H Tilly

K Wilson

机构：

[1] Institut d'Hématologie,Department of Hematology

[2] Hôpital Saint-Louis,undefined

[3] Medizinische Universitätsklinik II Hematology/Oncology,undefined

[4] Institut Català d'Oncologia,undefined

[5] Hospital Duran i Reynals,undefined

[6] Istituto Nazionale per lo Studio e la Cura dei Tumori,undefined

[7] University Hospital Göttingen,undefined

[8] Service d'Hématologie Clinique,undefined

[9] Hôpital Henri Mondor,undefined

[10] European Institute of Oncology,undefined

[11] Chaim Sheba Medical Center,undefined

[12] St George's Hospital,undefined

[13] University of London,undefined

[14] Hospital de la Santa Creu i Sant Pau,undefined

[15] Universidad Autonoma de Barcelona,undefined

[16] Centre Henri Becquerel,undefined

[17] School of Medicine,undefined

[18] Cardiff University,undefined

来源：

Bone Marrow Transplantation | 2007年 / 40卷

关键词：

non-Hodgkin's lymphoma; yttrium-90 ibritumomab tiuxetan; radiolabelled immunotherapy; stem cell transplantation; autologous; allogeneic;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Haematopoietic SCT is currently considered a therapeutic option mainly in relapsed or refractory non-Hodgkin's lymphoma (NHL) owing to high post-transplantation relapse rates and significant toxicity of conventional myeloablative conditioning for allogeneic SCT. Radiolabelled immunotherapy combines the benefits of monoclonal antibody targeting with therapeutic doses of radiation, and is a promising advance in the treatment of malignant lymphomas. It is now under investigation as a component of conditioning prior to SCT, with the aim of improving outcomes following SCT without increasing the toxicity of high-dose chemotherapy pre-transplant conditioning. An expert panel met at a European workshop in November 2006 to review the latest data on radiolabelled immunotherapy in the transplant setting, and its potential future directions, with a focus on 90Y-ibritumomab tiuxetan. They reviewed data on the combination of standard/high/escalating dose 90Y-ibritumomab tiuxetan with high-dose chemotherapy, and high/escalating dose 90Y-ibritumomab tiuxetan as the sole myeloablative agent, prior to autologous SCT, and also 90Y-ibritumomab tiuxetan as a component of reduced intensity conditioning prior to allogeneic SCT. The preliminary data are highly promising in terms of conditioning tolerability and patient outcomes following transplant; further phase II studies are now needed to consolidate these data and to investigate specific patient populations and NHL subtypes.

引用

页码：1007 / 1017

页数：10

共 190 条

[1]

Hahn T(2006)The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review Biol Blood Marrow Transplant 12 1-30

[2]

Wall D(1995)Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma N Engl J Med 333 1540-1545

[3]

Camitta B(2003)Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma Br J Haematol 122 457-464

[4]

Davies S(2003)High-dose myeloablative therapy and autologous peripheral blood progenitor cell transplantation for elderly patients (greater than 65 years of age) with relapsed large cell lymphoma Biol Blood Marrow Transplant 9 383-388

[5]

Dillon H(2003)Low transplant related mortality in older patients with hematologic malignancies undergoing autologous stem cell transplantation Haematologica 88 300-305

[6]

Gaynon P(2006)Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma Bone Marrow Transplant 37 1017-1022

[7]

Philip T(2001)Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older Bone Marrow Transplant 27 593-599

[8]

Guglielmi C(2005)Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older Leuk Lymphoma 46 1575-1579

[9]

Hagenbeek A(2006)Reduced-Intensity Regimens in Allogeneic Stem-Cell Transplantation for Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Hematology 2006 390-397

[10]

Somers R(2003)An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation Bone Marrow Transplant 31 667-678

← 1 2 3 4 5 6 7 8 9 10 →